Vimian Group AB (publ) (VIMIAN.ST)
SEK 42.2
(2.93%)
SEK 42.2
(2.93%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 973.68 Million EUR | 5.43% |
| 2022 | 923.55 Million EUR | 44.14% |
| 2021 | 640.71 Million EUR | 40.42% |
| 2020 | 456.29 Million EUR | 360.45% |
| 2019 | 99.09 Million EUR | 198.14% |
| 2018 | 33.23 Million EUR | 664660.0% |
| 2017 | 5000.00 EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 1.05 Billion EUR | 6.17% |
| 2024 Q2 | 996.53 Million EUR | 1.06% |
| 2024 Q1 | 986.12 Million EUR | 1.28% |
| 2023 FY | 973.68 Million EUR | 5.43% |
| 2023 Q3 | 1.01 Billion EUR | 0.08% |
| 2023 Q4 | 973.68 Million EUR | -4.0% |
| 2023 Q2 | 1.01 Billion EUR | 0.19% |
| 2023 Q1 | 1.01 Billion EUR | 9.51% |
| 2022 Q4 | 923.55 Million EUR | 2.68% |
| 2022 FY | 923.55 Million EUR | 44.14% |
| 2022 Q3 | 899.46 Million EUR | 5.92% |
| 2022 Q2 | 849.17 Million EUR | 5.52% |
| 2022 Q1 | 804.73 Million EUR | 25.6% |
| 2021 Q2 | 549.61 Million EUR | 15.23% |
| 2021 Q4 | 640.71 Million EUR | 14.33% |
| 2021 Q3 | 560.41 Million EUR | 1.97% |
| 2021 FY | 640.71 Million EUR | 40.42% |
| 2021 Q1 | 476.97 Million EUR | 4.53% |
| 2020 FY | 456.29 Million EUR | 360.45% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q4 | 456.29 Million EUR | 0.0% |
| 2019 FY | 99.09 Million EUR | 198.14% |
| 2018 FY | 33.23 Million EUR | 664660.0% |
| 2017 FY | 5000.00 EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AroCell AB (publ) | 174.89 Million SEK | -456.734% |
| Devyser Diagnostics AB (publ) | 510.1 Million SEK | -90.881% |
| Immunovia AB (publ) | 98.68 Million SEK | -886.699% |
| Prostatype Genomics AB (publ) | 49.22 Million SEK | -1878.148% |
| SenzaGen AB | 97.17 Million SEK | -901.98% |
| Spermosens AB | 26.1 Million SEK | -3629.876% |